<DOC>
	<DOCNO>NCT01252628</DOCNO>
	<brief_summary>The purpose Phase 1/2 open-label study determine safety efficacy cetuximab PX-866 combination treatment . In Phase 1 part study , dose PX-866 give combination cetuximab determine patient incurable metastatic CRC incurable progressive , recurrent metastatic SCCHN . The Phase 2 part study randomize evaluation antitumor activity safety PX-866 combination cetuximab versus cetuximab alone patient either incurable metastatic CRC history progression recurrence follow prior irinotecan oxaliplatin contain regimen intolerant irinotecan ( Group 1 ) incurable progressive , recurrent metastatic SCCHN ( Group 2 ) .</brief_summary>
	<brief_title>Phase 1 2 Study PX-866 Cetuximab</brief_title>
	<detailed_description>Phase 1 determine maximally tolerate recommend dose PX-866 give orally Days 1-21 combination cetuximab 250 mg/m2 administer IV weekly Days 1 , 8 , 15 21-day cycle . All patient receive initial load dose 400 mg/m2 cetuximab rather 250 mg/m2 Cycle 1 Day 1 . Patients may receive premedication H1 antagonist per cetuximab package insert . Up 3 dose level PX-866 evaluate determine MTD/RD cohort 6 patient use standard 3+3 dose-escalation design . At least 6 patient treated MTD/RD . All patient Phase 1 require undergo PK assessment Cycle 1 Week 3 measure cetuximab level . Exploratory PD assessment include evaluation change level fast C-peptide well change EGFR PI-3K signal pathway peripheral blood mononuclear cell ( PBMC ) platelet . Additional optional evaluation include change EGFR PI-3K signal paired tumor biopsy provide one cycle treatment . All patient ask , require , provide archive tumor biopsy sample evaluation potential biomarkers response PX-866 cetuximab . Phase 2 open-label , randomized evaluation antitumor activity safety PX-866 administer orally via PEG tube ( applicable ) MTD/RD combination cetuximab , versus cetuximab alone cetuximab-naïve patient incurable metastatic CRC history progression recurrence follow prior irinotecan oxaliplatin contain regimen intolerant irinotecan ( Group 1 ) patient incurable progressive , recurrent metastatic SCCHN ( Group 2 ) . Seventy two evaluable patient ( 36 patient per arm ) evaluate per indication . Patients randomize 1:1 receive PX-866 + cetuximab cetuximab alone .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>At least 18 year time consent Use medically accept form contraception time consent completion followup study visit If female childbearing potential , negative pregnancy test Signed informed consent Measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) Documentation available last prior systemic treatment include date treatment , best response treatment , duration best response , reason discontinuation treatment Eastern Cooperative Oncology Group ( ECOG ) 0 1 Group 1 : Patients incurable metastatic CRC history progression recurrence follow prior irinotecan oxaliplatin contain regimen . Patients history intolerance irinotecan base therapy ineligibility receive irinotecan also eligible long receive prior oxaliplatin contain regimen . Group 2 : Patients incurable SCCHN history progression recurrence follow least one prior platinum base chemotherapy chemotherapy/radiation contain regimen . Patients history intolerance platinum base therapy history ineligibility receive platinum base regimen also eligible . SCCHN patient receive cetuximab radiosensitizer locally advanced disease complete treatment least 6 month prior start study drug treatment eligible In opinion clinical investigator , life expectancy great 3 month Adequate hematologic function Adequate hepatic function Creatinine level ≤1.5 x ULN Serum magnesium ≥ LLN . Has medical , social , psychosocial factor , opinion investigator , could impact safety compliance study procedure Is breastfeed Treatment systemic chemotherapy , epidermal growth factor receptor ( EGFR ) inhibitor , radiation experimental agent within 4 week study drug dose Received prior cetuximab , except define inclusion criterion Previous treatment phosphatidylinositol 3kinase ( PI3K ) inhibitor Known human immunodeficiency virus ( HIV ) Poorly control diabetes mellitus ( IFCCHbA1C ≥ 53 mmol/mol DCCT HbA1C ≥ 7 % ) Kras mutation codon 12 13 ( CRC patient ) Known suspect clinically active brain metastasis . Previously treat stable brain metastasis allowable . Stable brain metastasis define change CT scan MRI minimum two month AND change steroid dose minimum four week , unless change due intercurrent infection acute event ) Any significant medical psychiatric condition opinion investigator render patient inadequate participation History severe hypersensitivity cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CRC</keyword>
	<keyword>SCCHN</keyword>
	<keyword>PX-866</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>ERBITUX</keyword>
	<keyword>Colon</keyword>
	<keyword>Head Neck</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>PI-3K</keyword>
	<keyword>PI3 kinase</keyword>
	<keyword>PI3K</keyword>
</DOC>